Literature DB >> 24140653

Androgen glucuronides analysis by liquid chromatography tandem-mass spectrometry: could it raise new perspectives in the diagnostic field of hormone-dependent malignancies?

Eleni Kalogera1, Constantinos Pistos, Xeni Provatopoulou, Sotirios Athanaselis, Chara Spiliopoulou, Antonia Gounaris.   

Abstract

Breast and prostate constitute organs of intense steroidogenic activity. Clinical and epidemiologic data provide strong evidence on the influence of androgens and estrogens on the risk of typical hormone-dependent malignancies, like breast and prostate cancer. Recent studies have focused on the role of androgen metabolites in regulating androgen concentrations in hormone-sensitive tissues. Steroid glucuronidation has been suggested to have a prominent role in controlling the levels and the biological activity of unconjugated androgens. It is well-established that serum levels of androgen glucuronides reflect androgen metabolism in androgen-sensitive tissues. Quantitative analysis of androgen metabolites in blood specimens is the only minimally invasive approach permitting an accurate estimate of the total pool of androgens. During the past years, androgen glucuronides analysis most often involved radioimmunoassays (RIA) or direct immunoassays, both methods bearing serious limitations. However, recent impressive technical advances in mass spectrometry, and particularly in high performance liquid chromatography coupled with mass spectrometry (LC-MS/MS), have overcome these drawbacks enabling the simultaneous, quantitative analysis of multiple steroids even at low concentrations. Blood androgen profiling by LC-MS/MS, a robust and reliable technique of high selectivity, sensitivity, specificity, precision and accuracy emerges as a promising new approach in the study of human pathology. The present review offers a contemporary insight in androgen glucuronides profiling through the application of LC-MS/MS, highlighting new perspectives in the study of steroids and their implication in hormone-dependent malignancies.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3α-diol; 3α-diol-17G; 3α-diol-3G; 3α-diol-G; 4-Dione; 4-androstenedione; 5α-androstane-3β, 17β-diol; A-diol; ADT; ADTG; APCI; APPI; Aanediol; Aenediol; Androgen glucuronides; DHEA; DHEAS; DHT; ER; ER-α; ESI; GC–MS; HSD; Hormone-dependent malignancies; IS; LC–MS; LC–MS/MS; LLE; LLOQ; Liquid chromatography; MRM; Mass spectrometry; QTrap; Quantitative analysis; RIA; Review; SHBG; SPE; T; UDPGA; UHPLC-QTOF-MS; androst-5-ene-3β, 17β-diol; androstane-3α, 17β-diol; androstane-3α, 17β-diol-17-glucuronide; androstane-3α, 17β-diol-3-glucuronide; androstane-3α, 17β-diol-glucuronide; androstene-3β, 17β-diol; androsterone; androsterone glucuronide; atmospheric pressure chemical ionization; atmospheric pressure photo ionization; dehydroepiandrosterone; dehydroepindrosterone sulfate; dihydrotestosterone; electrospray ionization interface; estrogen receptor-α; estrogenic receptor; gas chromatography–mass spectrometry; hybrid linear ion trap-triple quadrupole mass spectrometer; hydroxysteroid dehydrogenase; internal standard; liquid chromatography–mass spectrometry; liquid chromatography–tandem mass spectrometry; liquid–liquid extraction; lower limit of quantification; multiple reaction monitoring; radioimmunoassay; sex hormone-binding globulin; solid phase extraction; testosterone; ultra-high pressure liquid chromatography quadrupole time-of-flight mass spectrometer; uridine-5′-diphosphoglucuronic acid

Mesh:

Substances:

Year:  2013        PMID: 24140653     DOI: 10.1016/j.jchromb.2013.09.022

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  Nutritional metabolomics and breast cancer risk in a prospective study.

Authors:  Mary C Playdon; Regina G Ziegler; Joshua N Sampson; Rachael Stolzenberg-Solomon; Henry J Thompson; Melinda L Irwin; Susan T Mayne; Robert N Hoover; Steven C Moore
Journal:  Am J Clin Nutr       Date:  2017-06-28       Impact factor: 7.045

Review 2.  Recent advances in simultaneous analysis of bisphenol A and its conjugates in human matrices: Exposure biomarker perspectives.

Authors:  Syam S Andra; Christine Austin; Juan Yang; Dhavalkumar Patel; Manish Arora
Journal:  Sci Total Environ       Date:  2016-08-30       Impact factor: 7.963

3.  Bioanalytical LC-MS Method for the Quantification of Plasma Androgens and Androgen Glucuronides in Breast Cancer.

Authors:  Eleni Kalogera; Constantinos Pistos; Xeni Provatopoulou; Costas A Christophi; George C Zografos; Maria Stefanidou; Chara Spiliopoulou; Sotirios Athanaselis; Antonia Gounaris
Journal:  J Chromatogr Sci       Date:  2016-01-12       Impact factor: 1.618

4.  Metabolic profiling putatively identifies plasma biomarkers of male infertility using UPLC-ESI-IT-TOFMS.

Authors:  F J Zeng; H C Ji; Z M Zhang; J K Luo; H M Lu; Y Wang
Journal:  RSC Adv       Date:  2018-07-19       Impact factor: 4.036

5.  Components of the human-specific, p53-mediated "kill switch" tumor suppression mechanism are usurped by human tumors, creating the possibility of therapeutic exploitation.

Authors:  Jonathan Nyce
Journal:  Cancer Drug Resist       Date:  2019-12-19

6.  Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients.

Authors:  Anindita Ravindran; Kimiko L Krieger; Akash K Kaushik; Hélène Hovington; Sadia Mehdi; Danthasinghe Waduge Badrajee Piyarathna; Vasanta Putluri; Paul Basil; Uttam Rasaily; Franklin Gu; Truong Dang; Jong Min Choi; Rajni Sonavane; Sung Yun Jung; Lisha Wang; Rohit Mehra; Nancy L Weigel; Nagireddy Putluri; David R Rowley; Ganesh S Palapattu; Chantal Guillemette; Louis Lacombe; Éric Lévesque; Arun Sreekumar
Journal:  Cells       Date:  2022-07-29       Impact factor: 7.666

Review 7.  Intracrine androgen biosynthesis, metabolism and action revisited.

Authors:  Lina Schiffer; Wiebke Arlt; Karl-Heinz Storbeck
Journal:  Mol Cell Endocrinol       Date:  2017-09-01       Impact factor: 4.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.